3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
3
Uveal Melanoma
1
Urologic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
6
cemiplimab
3
Cyclophosphamide
3
temsirolimus
2
palbociclib
2
cediranib
2
Therapeutics
2
Radiotherapy
2
Radiosurgery
2
Psychiatric Rehabilitation
2
Paclitaxel
2
Oxaliplatin
2
Nivolumab
2
Methods
2
Magnetic Resonance Spectroscopy
2
Leucovorin
2
Gemcitabine
2
Fluorouracil
2
Drug Therapy
2
Docetaxel
2
Cisplatin
2
Capecitabine
2
Biological Therapy
2
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
tanespimycin
1
sonidegib
1
sargramostim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
niraparib
×
Dermatologic
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts